Regeneron Pharmaceuticalsannounced that the Phase 3 Panorama trial evaluating Eylea (aflibercept) Injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year (52-week) primary endpoint and key secondary endpoints. On the primary endpoint at one year, 80 percent and 65 percent of patients receiving Eylea on an every 8- and every 16-week interval…
FDA To Conduct Priority Review Of Cemiplimab
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery. Advanced CSCC is the deadliest non-melanoma skin cancer. Cemiplimab is…
Regeneron’s Diabetic Retinopathy Injection Garners Topline Positive Results
Eylea (aflibercept) injection demonstrates positive topline results in Phase 3 non-proliferative diabetic retinopathy trial. Regeneron Pharmaceuticals, Inc.’s Phase 3 PANORAMA trial evaluating Eylea (aflibercept) Injection in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its 24-week primary endpoint. In the trial, 58 percent of Eylea-treated patients experienced a two-step or greater improvement from baseline on…
